Cargando…

Voriconazole Pharmacokinetics Are Not Altered in Critically Ill Patients with Acute-on-Chronic Liver Failure and Continuous Renal Replacement Therapy: An Observational Study

Infection and sepsis are a main cause of acute-on-chronic liver failure (ACLF). Besides bacteria, molds play a role. Voriconazole (VRC) is recommended but its pharmacokinetics (PK) may be altered by ACLF. Because ACLF patients often suffer from concomitant acute renal failure, we studied the PK of V...

Descripción completa

Detalles Bibliográficos
Autores principales: Grensemann, Jörn, Pfaffendorf, Christoph, Wicha, Sebastian G., König, Christina, Roedl, Kevin, Jarczak, Dominik, Iwersen-Bergmann, Stefanie, Manthey, Carolin, Kluge, Stefan, Fuhrmann, Valentin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538714/
https://www.ncbi.nlm.nih.gov/pubmed/34683408
http://dx.doi.org/10.3390/microorganisms9102087
_version_ 1784588573099425792
author Grensemann, Jörn
Pfaffendorf, Christoph
Wicha, Sebastian G.
König, Christina
Roedl, Kevin
Jarczak, Dominik
Iwersen-Bergmann, Stefanie
Manthey, Carolin
Kluge, Stefan
Fuhrmann, Valentin
author_facet Grensemann, Jörn
Pfaffendorf, Christoph
Wicha, Sebastian G.
König, Christina
Roedl, Kevin
Jarczak, Dominik
Iwersen-Bergmann, Stefanie
Manthey, Carolin
Kluge, Stefan
Fuhrmann, Valentin
author_sort Grensemann, Jörn
collection PubMed
description Infection and sepsis are a main cause of acute-on-chronic liver failure (ACLF). Besides bacteria, molds play a role. Voriconazole (VRC) is recommended but its pharmacokinetics (PK) may be altered by ACLF. Because ACLF patients often suffer from concomitant acute renal failure, we studied the PK of VRC in patients receiving continuous renal replacement therapy (RRT) with ACLF and compared it to PK of VRC in critically ill patients with RRT without concomitant liver failure (NLF). In this prospective cohort study, patients received weight-based VRC. Pre- and post-dialysis membrane, and dialysate samples obtained at different time points were analyzed by high-performance liquid chromatography. An integrated dialysis pharmacometric model was used to model the available PK data. The recommended, 50% lower, and 50% higher doses were analyzed by Monte-Carlo simulation (MCS) for day 1 and at steady-state with a target trough concentration (TC) of 0.5–3mg/L. Fifteen patients were included in this study. Of these, 6 patients suffered from ACLF. A two-compartment model with linear clearance described VRC PK. No difference for central (V1) or peripheral (V2) volumes of distribution or clearance could be demonstrated between the groups. V1 was 80.6L (95% confidence interval: 62.6–104) and V2 106L (65–166) with a body clearance of 4.7L/h (2.87–7.81) and RRT clearance of 1.46L/h (1.29–1.64). MCS showed TC below/within/above target of 10/74/16% on day 1 and 9/39/52% at steady-state for the recommended dose. A 50% lower dose resulted in 26/72/1% (day 1) and 17/64/19% at steady-state and 7/57/37% and 7/27/67% for a 50% higher dose. VRC pharmacokinetics are not significantly influenced by ACLF in critically ill patients who receive RRT. Maintenance dose should be adjusted in both groups. Due to the high interindividual variability, therapeutic drug monitoring seems inevitable.
format Online
Article
Text
id pubmed-8538714
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85387142021-10-24 Voriconazole Pharmacokinetics Are Not Altered in Critically Ill Patients with Acute-on-Chronic Liver Failure and Continuous Renal Replacement Therapy: An Observational Study Grensemann, Jörn Pfaffendorf, Christoph Wicha, Sebastian G. König, Christina Roedl, Kevin Jarczak, Dominik Iwersen-Bergmann, Stefanie Manthey, Carolin Kluge, Stefan Fuhrmann, Valentin Microorganisms Article Infection and sepsis are a main cause of acute-on-chronic liver failure (ACLF). Besides bacteria, molds play a role. Voriconazole (VRC) is recommended but its pharmacokinetics (PK) may be altered by ACLF. Because ACLF patients often suffer from concomitant acute renal failure, we studied the PK of VRC in patients receiving continuous renal replacement therapy (RRT) with ACLF and compared it to PK of VRC in critically ill patients with RRT without concomitant liver failure (NLF). In this prospective cohort study, patients received weight-based VRC. Pre- and post-dialysis membrane, and dialysate samples obtained at different time points were analyzed by high-performance liquid chromatography. An integrated dialysis pharmacometric model was used to model the available PK data. The recommended, 50% lower, and 50% higher doses were analyzed by Monte-Carlo simulation (MCS) for day 1 and at steady-state with a target trough concentration (TC) of 0.5–3mg/L. Fifteen patients were included in this study. Of these, 6 patients suffered from ACLF. A two-compartment model with linear clearance described VRC PK. No difference for central (V1) or peripheral (V2) volumes of distribution or clearance could be demonstrated between the groups. V1 was 80.6L (95% confidence interval: 62.6–104) and V2 106L (65–166) with a body clearance of 4.7L/h (2.87–7.81) and RRT clearance of 1.46L/h (1.29–1.64). MCS showed TC below/within/above target of 10/74/16% on day 1 and 9/39/52% at steady-state for the recommended dose. A 50% lower dose resulted in 26/72/1% (day 1) and 17/64/19% at steady-state and 7/57/37% and 7/27/67% for a 50% higher dose. VRC pharmacokinetics are not significantly influenced by ACLF in critically ill patients who receive RRT. Maintenance dose should be adjusted in both groups. Due to the high interindividual variability, therapeutic drug monitoring seems inevitable. MDPI 2021-10-03 /pmc/articles/PMC8538714/ /pubmed/34683408 http://dx.doi.org/10.3390/microorganisms9102087 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Grensemann, Jörn
Pfaffendorf, Christoph
Wicha, Sebastian G.
König, Christina
Roedl, Kevin
Jarczak, Dominik
Iwersen-Bergmann, Stefanie
Manthey, Carolin
Kluge, Stefan
Fuhrmann, Valentin
Voriconazole Pharmacokinetics Are Not Altered in Critically Ill Patients with Acute-on-Chronic Liver Failure and Continuous Renal Replacement Therapy: An Observational Study
title Voriconazole Pharmacokinetics Are Not Altered in Critically Ill Patients with Acute-on-Chronic Liver Failure and Continuous Renal Replacement Therapy: An Observational Study
title_full Voriconazole Pharmacokinetics Are Not Altered in Critically Ill Patients with Acute-on-Chronic Liver Failure and Continuous Renal Replacement Therapy: An Observational Study
title_fullStr Voriconazole Pharmacokinetics Are Not Altered in Critically Ill Patients with Acute-on-Chronic Liver Failure and Continuous Renal Replacement Therapy: An Observational Study
title_full_unstemmed Voriconazole Pharmacokinetics Are Not Altered in Critically Ill Patients with Acute-on-Chronic Liver Failure and Continuous Renal Replacement Therapy: An Observational Study
title_short Voriconazole Pharmacokinetics Are Not Altered in Critically Ill Patients with Acute-on-Chronic Liver Failure and Continuous Renal Replacement Therapy: An Observational Study
title_sort voriconazole pharmacokinetics are not altered in critically ill patients with acute-on-chronic liver failure and continuous renal replacement therapy: an observational study
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8538714/
https://www.ncbi.nlm.nih.gov/pubmed/34683408
http://dx.doi.org/10.3390/microorganisms9102087
work_keys_str_mv AT grensemannjorn voriconazolepharmacokineticsarenotalteredincriticallyillpatientswithacuteonchronicliverfailureandcontinuousrenalreplacementtherapyanobservationalstudy
AT pfaffendorfchristoph voriconazolepharmacokineticsarenotalteredincriticallyillpatientswithacuteonchronicliverfailureandcontinuousrenalreplacementtherapyanobservationalstudy
AT wichasebastiang voriconazolepharmacokineticsarenotalteredincriticallyillpatientswithacuteonchronicliverfailureandcontinuousrenalreplacementtherapyanobservationalstudy
AT konigchristina voriconazolepharmacokineticsarenotalteredincriticallyillpatientswithacuteonchronicliverfailureandcontinuousrenalreplacementtherapyanobservationalstudy
AT roedlkevin voriconazolepharmacokineticsarenotalteredincriticallyillpatientswithacuteonchronicliverfailureandcontinuousrenalreplacementtherapyanobservationalstudy
AT jarczakdominik voriconazolepharmacokineticsarenotalteredincriticallyillpatientswithacuteonchronicliverfailureandcontinuousrenalreplacementtherapyanobservationalstudy
AT iwersenbergmannstefanie voriconazolepharmacokineticsarenotalteredincriticallyillpatientswithacuteonchronicliverfailureandcontinuousrenalreplacementtherapyanobservationalstudy
AT mantheycarolin voriconazolepharmacokineticsarenotalteredincriticallyillpatientswithacuteonchronicliverfailureandcontinuousrenalreplacementtherapyanobservationalstudy
AT klugestefan voriconazolepharmacokineticsarenotalteredincriticallyillpatientswithacuteonchronicliverfailureandcontinuousrenalreplacementtherapyanobservationalstudy
AT fuhrmannvalentin voriconazolepharmacokineticsarenotalteredincriticallyillpatientswithacuteonchronicliverfailureandcontinuousrenalreplacementtherapyanobservationalstudy